Metrohm USA Opens Its New Headquarters in Florida
Metrohm USA welcomes its Tampa employees to their new North American headquarters in Riverview, Florida. Since breaking ground in February 2017, the 90,000 square foot state-of-the-art facility has evolved into a space that exemplifies Metrohm’s continued commitment to its customers and employees.
“Metrohm’s dedication to the people that use our instruments and those who support them make us who we are as a company. This new facility demonstrates our commitments as we invest in providing our customers with innovative training facilities and our employees with modern and collaborative work areas,” says Edward Colihan, President and CEO of Metrohm USA. “This is a significant moment for Metrohm USA and I’m excited to introduce a facility that will support our growth for years to come.”
Innovation and collaboration are the major themes that run throughout the entire building, including training facilities for customers and employees, application development laboratories, technical and customer support areas and a 25,000 square foot warehouse. The modern and open layout is intended to enhance creativity and teamwork.
The new building is located at 9250 Camden Field Parkway in Riverview, Florida. A grand opening and ribbon cutting event will take place in mid-April in conjunction with Metrohm’s 75th anniversary.
Research Team Discovers Compound that Stops Cancer From SpreadingNews
Using a mouse model, OHSU physician-scientists lead effort to hone a drug that inhibits cancer cells from spreading to other areas in the body.READ MORE
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE
Combining Different Malaria Vaccines Could Reduce Cases by 91%News
Using two experimental anti-malarial vaccines, which work in different ways, can greatly reduce the number of malaria infections in animal studies. Experimental vaccines, which independently achieve 48% and 68% reductions in malaria cases, can achieve 91% reduction when combined.